Reviewed by Michael Gill, B. Sc.

What Are Anoro Ellipta Clinical Trials?

At the time of this writing, at least eight major clinical trials are underway concerning potential treatments using Anoro Ellipta. These include a study involving patients with long-term lung diseases. Anoro Ellipta is being studied for its effects on pulmonary physiologic responses to COPD treatments.

Anoro Ellipta is being studied for use in different forms in addition to its traditional powder form which is used through inhalation. It is also being studied for its effects on healthy volunteers, asthmatic patients, and COPD patients as a pure comparison study.

Finally, another interesting research project is looking into the use of Anoro Ellipta concerning lung hyperinflation, and sympathetic nerve activity as it relates to the stiffness of large arteries in COPD Patients

Why Is Anoro Ellipta Being Studied In Clinical Trials?

Anoro Ellipta is well known for its effectiveness in opening up airways for the treatment or prevention of obstructions caused by COPD, acute asthmatic flare-ups, and other medical emergencies. As a result of its facility in this regard, Anoro Ellipta is the subject of much interest in the treatment of all manner of lung disorders.

The drug can be used to boost blood oxygen levels temporarily, either with or without the use of supplemental oxygen. It may also be possible to use it as a means of easing surgical procedures in and around the lungs.

Finally, the therapeutic use of Anoro Ellipta may be used to increase contact between other inhaled substances and the tissues of the lungs to boost blood oxygen, enhance the effects of inhaled anesthesia, and much more.

How Does Anoro Ellipta Treatment Work?

Anoro Ellipta is a powder made to be inhaled as a treatment for acute bronchospasm episodes. It is to be used in emergencies in which breathing becomes restricted due to an asthmatic episode or asthma-like asthmatic response, though it is not used for the treatment of asthma strictly speaking.

Anoro Ellipta is a potent bronchodilator that can also be used to prevent obstruction of the airway and to lower the incidence of flare-ups in adults suffering from chronic obstructive pulmonary disease (COPD).

It should be noted that Anoro Ellipta is used and prescribed only to and for adults with COPD, and is not used as a treatment for asthma.

What Are Some of the Breakthrough Clinical Trials Involving Anoro Ellipta?

Because blood oxygen levels are considered a key indicator of the possibility of imminent death or necrosis, Anoro Ellipta is considered to be one of the most important life-saving drugs available to modern clinicians. That being the case, the studies into the potential uses for this substance are many. Here are a few noteworthy examples;

Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics Safety, and Tolerability in Patients With Long-term Lung Diseases

A New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

Who Are The Key Opinion Leaders On Anoro Ellipta Clinical Trial Research?

Kaci Durbin, MD.

Gary L. Pierce Ph.D., Principal Investigator, University of Iowa

GlaxoSmithKline (GSK)

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: November 6th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.